Tacalyx GmbH
Tacalyx develops the next generation of anti-Cancer therapeutics in indications with high medical need
Tacalyx develops the next generation of anti-Cancer therapeutics in indications with high medical need
Tacalyx GmbH is a Germany-based biotechnology startup founded in 2019. The company is dedicated to developing innovative anti-cancer therapeutics to address the limited treatment options for metastatic malignant tumors. Tacalyx focuses on targeting cancer-specific carbohydrate antigens, known as Tumor Associated Carbohydrate Antigens (TACAs), found on the surfaces of cancer cells. These abnormal glycans are highly specific to cancer and play a significant role in tumor progression and virulence. With a recent €7.00M Seed Round investment from Thuja Capital in 11 June 2024, Tacalyx is poised to advance its promising research and development efforts in high-need cancer indications. Their compelling approach to addressing crucial unmet medical needs positions the company as an exciting prospect in the biotechnology, health care, health and wellness, and life sciences industries.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Seed Round | €7.00M | 1 |
|
11 Jun 2024 |
| Seed Round | €7.00M | 6 |
|
25 Sep 2019 |
No recent news or press coverage available for Tacalyx GmbH.
We care about your data, and we'd love to use cookies make your experience better.